MYM Nutraceuticals Inc., (CSE:MYM) (the “Company” or “MYM”) is pleased to announce the following corporate updates:
MYM Engages Michael Horsfall to Consulting Agreement
MYM shall engage the consultant for a 3-year consulting term commencing on November 23, 2017. Michael Horsfall shall provide MYM with consulting services focused on helping MYM and its partners obtain a license for and construct a medical marijuana production facility in Richmond Valley, Australia. In lieu of consulting fees, MYM shall grant 140,000 options to purchase common shares in the capital of MYM, with an exercise price of $3.37. The options shall vest in accordance with the following schedule, and expire one year after vesting:
(a) 14,000 on the 3-month anniversary of the Effective Date;
(b) 14,000 on the 6-month anniversary of the Effective Date;
(c) 14,000 on the 9-month anniversary of the Effective Date;
(d) 14,000 on the 12-month anniversary of the Effective Date;
(e) 14,000 on the 15-month anniversary of the Effective Date;
(f) 14,000 on the 18-month anniversary of the Effective Date;
(g) 14,000 on the 21-month anniversary of the Effective Date;
(h) 14,000 on the 24-month anniversary of the Effective Date;
(i) 14,000 on the 27-month anniversary of the Effective Date; and
(j) 14,000 on the 30-month anniversary of the Effective Date.
Mr. Horsfall is co-founder and CEO of PUF Ventures Australia Pty and Natures Hemp Australia Pty Ltd.
Mr. Horsfall has worked extensively as a strategic business consultant with various Australian and Internationally listed fortune 100 companies and brings over 20 years’ experience to the role. He has been responsible for successfully leading pursuit and capture teams across Government and Whole-of-Government (WOG) IT Outsourcing Contracts for both Federal and State Governments. Mr. Horsfall has founded numerous companies in the Information Technology, Consulting, Finance, Hospitality and Real Estate sectors. He brings with him an extensive network and relationships combined with an in-depth understanding of business and Government.
MYM Engages Camber Digital to Consulting Agreement
MYM shall engage the consultant for a 1-year consulting term, commencing on January 1, 2018. Camber Digital shall provide MYM with marketing, branding, graphic design, and IT services. MYM shall grant Camber Digital 60,000 options to purchase common shares in the capital of MYM, with an exercise price of $3.37. The options shall vest in accordance with the following schedule, and expire one year after vesting:
- (a) 15,000 on the 3-month anniversary of the Start Date;
(b) 15,000 on the 6-month anniversary of the Start Date;
(c) 15,000 on the 9-month anniversary of the Start Date; and
(d) 15,000 on the 12-month anniversary of the Start Date.
MYM Assigns Shares Under Debt Settlement Agreement
MYM assigns to Chrome Holdings (“Chrome”) 175,000 common shares in the capital of MYM to satisfy obligations under the Finder’s Agreement. Chrome, MYM and PUF Ventures Australia are participants in a joint venture to build a medical marijuana facility in Richmond Valley, Australia (“PUF Deal”). MYM owes a finder’s fee equal to 5% of the value of the PUF Deal. Chrome wishes to assume MYM’s obligations under the Finder’s Agreement with respect to the payment of the debt.
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Quebec that when completed will have over 1.5 million sf of production space. MYM is also a partner in a 1.2 million sf production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
ON BEHALF OF THE BOARD
Rob Gietl, CEO
MYM Nutraceuticals Inc.
Join us on our social media channels:
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
Click here to connect with MYM Nutraceuticals Inc. (CSE:MYM) for an Investor Presentation.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.